The Preclinical IPO Comeback Continues With Septerna’s $158m Goal
Septerna’s plans shows companies are once again daring to undertake IPOs without Phase I data – though share movements this year show many face a rough ride on the public markets.
Septerna’s plans shows companies are once again daring to undertake IPOs without Phase I data – though share movements this year show many face a rough ride on the public markets.